Merck’s Keytruda (pembrolizumab) + Chemotherapy Receive NMPA’s (CFDA) Approval for 1L Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Merck’s Keytruda (pembrolizumab) + Chemotherapy Receive NMPA’s (CFDA) Approval for 1L Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Shots:

  • The approval is based on P-III KEYNOTE-189 trial assessing Keytruda + pemetrexed & Pt CT in patients with 1L metastatic non-sq NSCLC, with no EGFR or ALK genomic tumor aberrations regardless of PD-L1 tumor expression status
  • The P-III KEYNOTE-189 trial resulted in improvement in OS, reduction in the risk of death by half, improvement in PFS
  • Keytruda (pembrolizumab) 100mg is an anti-PD-1 therapy involves blocking of the interaction between PD-1 and its ligands i.e PD-L1 & PD- L2 and is evaluated in 900 trial globally in oncology

Click here to read full press release/ article | Ref: Merck & Co. | Image: WSJ